Healthcare is one of those sectors that just keeps working, regardless of what's happening in the broader market. Think about it - people need medical services and pharmaceutical products in bull markets and bear markets alike. That defensive quality is exactly why health mutual funds have become such a solid choice for investors looking to build stable portfolios.

What makes this sector particularly interesting is that many healthcare companies throw off consistent dividends. When a company can reliably pay dividends through different market cycles, you know it's got solid fundamentals and steady cash generation. That's the kind of stability most investors are actually looking for.

Mutual funds give you an easy way into this space without having to pick individual stocks. You get instant diversification and professional management analyzing which companies are worth owning. I've been looking at some of the top-ranked health mutual funds lately, and three names keep showing up as genuinely strong performers.

Franklin Strategic Biotechnology Discovery Fund (FBDIX) is one that caught my attention. This fund focuses on biotech companies and discovery research firms, with some flexibility to invest in other securities if opportunities arise. The numbers are pretty solid - it was posting 20.9% annualized returns over three years as of mid-2025. As of July that year, it held 77 different positions with about 7.5% in Gilead Sciences. That kind of diversification within the biotech space is what you want to see.

Then there's Fidelity Select Biotechnology (FBIOX). This one takes a similar approach but casts a wider net across both domestic and foreign biotech companies. The fund managers use fundamental analysis to pick stocks - looking at financial health, industry positioning, and broader market conditions. The three-year returns were running at 15.1% with a reasonable 0.63% expense ratio. For a specialized health mutual fund, that expense ratio is actually pretty competitive.

The third one worth considering is Fidelity Advisor Health Care Fund (FACTX). This one's a bit broader - it invests in any companies involved in healthcare products or services, not just biotech. Edward Yoon has been managing it since 2008, which speaks to some continuity. Five-year annualized returns came in at 5.6%, which is more conservative than the biotech-focused funds but still solid for a diversified healthcare play.

All three of these health mutual funds earned top rankings from Zacks, which basically means they're expected to outperform their peers going forward. If you're looking to add some defensive positioning to your portfolio, the healthcare sector through these kinds of funds is worth seriously considering. The combination of stable demand, dividend payments, and professional management makes them interesting for investors thinking about longer-term wealth building.